MUMBAI, India, Aug. 22 -- Intellectual Property India has published a patent application (202517066954 A) filed by Xyphos Biosciences Inc., San Francisco, on July 14, for 'chimeric antigen receptor and antibody-nkg2d ligand domain fusion protein.'
Inventor(s) include Kim, Kaman, C.; and Kearney, Alper, Yetil.
The application for the patent was published on Aug. 22, under issue no. 34/2025.
According to the abstract released by the Intellectual Property India: "The disclosure provides a chimeric antigen receptor comprising a mutated NKG2D ectodomain, an lgG4 hinge domain, a transmembrane domain, an intracellular signaling domain, and a costimulatory domain. The disclosure further provides an antibody fusion protein comprising antibody heavy chains and antibody light chains, wherein the heavy chains or the light chains are fused at their N-terminus via an amino acid linker to an A1-A2 domain comprising an amino acid sequence having at least 95% identity to SEQ ID NO: 11. The disclosure further provides a kit comprising one or more containers comprising the antibody fusion protein and/or comprising one or more containers comprising an immune cell, as well as methods of use, also are provided."
The patent application was internationally filed on Feb. 06, 2024, under International application No.PCT/US2024/014536.
Disclaimer: Curated by HT Syndication.
